Summary
The provided evaluation content is largely consistent with the supplied FDA label sections on pregnancy/embryo-fetal toxicity (contraindication in pregnancy, exclude pregnancy prior to initiation, effective contraception during treatment and for two weeks after discontinuation, and discontinue as soon as possible if pregnancy is detected). However, the label-related evaluation does not assess or score the separate generic-availability statements, which are off-topic relative to the prescribing information excerpts provided.
Category Scores
Accurate Statements
VANRAFIA is contraindicated in pregnant patients.
4.1 — Pregnancy; 8.1 — Pregnancy; 8.3 — Females and Males of Reproductive Potential
Exclude pregnancy prior to initiation of VANRAFIA.
2.1 — Pregnancy Testing; 5.1 — Embryo-Fetal Toxicity; 8.3 — Females and Males of Reproductive Potential
Patients who can become pregnant should use effective contraception prior to initiation, during treatment, and for two weeks after discontinuation.
5.1 — Embryo-Fetal Toxicity; 8.3 — Females and Males of Reproductive Potential; Medication Guide
When pregnancy is detected, discontinue VANRAFIA as soon as possible.
5.1 — Embryo-Fetal Toxicity
The Medication Guide emphasizes serious birth defects if taken during pregnancy and advises not being pregnant when starting and for two weeks after stopping.
Medication Guide — “What is the most important information I should know about VANRAFIA?”
Unsupported Statements
There is no confirmed, widely available generic version of Vanflyta (vanrafia) based on the information provided here.
Not supported by the supplied FDA prescribing information excerpts (pregnancy/embryo-fetal toxicity sections only).
A generic typically becomes available only after exclusivity periods and patent protections for the original product expire, and after the generic manufacturer submits an approved application and the product is launched.
Not addressed in the supplied prescribing information excerpts.
If exclusivity periods and patent protections have not expired and the generic has not been approved and launched, a generic may not be on the market yet.
Not addressed in the supplied prescribing information excerpts.
A generic may be checked for availability in the US using FDA’s Drugs@FDA database.
Not addressed in the supplied prescribing information excerpts.
An authorized generic may be sold before an open generic launch.
Not addressed in the supplied prescribing information excerpts.
Whether an authorized generic exists for Vanflyta/vanrafia depends on specific regulatory and commercial decisions in the market.
Not addressed in the supplied prescribing information excerpts.
Generic availability depends on the country.
Not addressed in the supplied prescribing information excerpts.
Contradictions
Important Omissions
No explicit label-citation/assessment provided for counseling that the available human data do not establish the presence/absence of major birth defects related to VANRAFIA (5.1).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The pregnancy-related safety statements that were evaluated are aligned with the label (contraindication in pregnancy, pregnancy exclusion prior to initiation, effective contraception for two weeks after discontinuation, and discontinue as soon as possible if pregnancy is detected). Off-topic generic-availability statements are not safety claims within the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some generic-availability statements are not supported by the supplied prescribing information excerpts and are off-topic relative to the label sections provided.
Suggested Improvement
Limit claims to what is covered by the FDA label excerpts provided (pregnancy/embryo-fetal toxicity) and ensure any non-label topics (e.g., generic availability) are either supported by relevant label/official sources or omitted from label alignment assessment.